Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cytogenix And Baylor College of Medicine to Conduct Pre-Clinical Testing Of An Aerosol Gene-Silencing Agent Against Cancer In The Lung
HOUSTON--(BUSINESS WIRE)--Jan. 21, 2004--CytoGenix Inc. (OTCBB:CYGX - News) has entered into an agreement with scientists at Baylor College of Medicine for experiments using a combination of the company's ssDNA expression vector technology and Baylor's proprietary aerosol gene delivery technology against a gene that, when silenced, inhibits tumor metastasis.
Dr. Charles L. Densmore, assistant professor, department of molecular physiology and biophysics, will direct these studies to determine the effect this novel gene delivery and silencing system has on cancer in the lungs of mice. Dr. Densmore is the inventor of this aerosol gene delivery system. He has pioneered its use for lung cancer, asthma and other pulmonary disorders.
Dr. Densmore stated, "The combination of these technologies has great potential for treating metastatic lung cancers and other difficult to treat pulmonary disorders. Our aerosol technology is non-invasive, and delivers directly to airway epithelial and pulmonary surfaces, thus avoiding many of the problems associated with intravenous delivery such as interaction with serum proteins, and difficulties in penetrating lung endothelial barriers."
Dr. Malcolm Skolnick, chairman and CEO of CytoGenix, stated, "We are very excited about the potential development of a very important clinical application of our ssDNA expression vector. Metastatic lung tumors are important targets because several cancers such as melanoma, breast and prostate tend to metastasize in the lungs."
CytoGenix Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the Web site at www.cytogenix.com.
Contact:
CytoGenix, Houston Juan Ferreira, 407-774-9949
Source
lung cancer
Charles Densmore, PhD
Developing and testing treatments in the laboratory for later possible clinical use is also one goal of Vernon Knight, MD, and Charles Densmore, PhD, both of the molecular physiology and biophysics department. Knowing that disruptions in the p53 pathway are the major causes of lung cancer, they have developed a method of using aerosol gene therapy to deliver functional p53 to cancerous lung cells.
This technology involves combining a positively charged molecule called polyethyleneiminine with negatively charged DNA encoding for p53. The two form a complex that can survive the harsh physiological climate of the lungs, enter the cells lining the airways, and deposit the DNA in the nucleus where it is expressed. "We found two very different mouse models of lung cancer in which we've been able to fairly consistently show inhibition," said Densmore.
One of the models is human p53 null osteosarcoma cells that are injected into the lungs of immunodeficient mice, done in collaboration with Eugenie Kleinerman at M.D. Anderson, while the other model is of mouse melanoma. "One of the things we think is going on, is that as p53 is expressed in these cells very efficiently, it leads to the up-regulation and the down-regulation of some genes that have an effect on the process of angiogenesis," said Densmore. Without angiogenesis, in which new blood vessels are formed, the tumors will starve and die.
Not content with using only one agent for aerosol therapy, these researchers are also looking at the effect of combining p53 gene therapy with radiation therapy or aerosolized treatments of chemotherapeutic drugs, including 9-nitrocamptothecin, itself in the first stages of clinical trials. "We have to build a whole structure of cancer therapy," said Knight. "We have to determine usefulness of each product as well as combinations of products
lung cancer
Dr Malcolm on American scene a must listen ,very very good interview.Takes about 8 minutes to down load.
http://archives.warpradio.com/btr/AmericanScene/080310.MP3
Malcolm on American scene it is excellent,about 7 min to download .
http://archives.warpradio.com/btr/AmericanScene/080310.MP3
Malcolm talked about Baylor and the test for lung cancer is going very well.This is the study that may put us on the radar for big investors.
http://archives.warpradio.com/btr/AmericanScene/080310.MP3
Sukycospito it has been only a month ago that Jesup & Lamont was hired give it a chance financing would be a major PR.I am willing to bet that you would lose your bet on that one .Suky did you happen to Google{ ssDNA } and did you find anything?
Sukycospito If you would like to start googling ssDNA this is our patented technology just to see how many companies are infringing on our patent ,just curious.Thank you.
arnold this is why I am not worried about Cytogenix ,we build a solid foundation of patents and the financing we flow.
http://www.bbbiotech.ch/index.cfm?action=industrienews.detail_IndustryNews&IndustryId=44834
http://www.hivdent.org/researcht/resnewsGFGU082003.htm
Gates gives 30 million to study the link between herpes and HIV and with just a fraction of that money GYGX could go to phase 3 and cure people with herpes,go figure?
Half way through the first hour on American scene Malcolm is on ,seems a repeat of the one a few days ago but still very interesting.
Thank's Sukycospito for your hard work finding these interesting Google articles Keep up the great work thanks again .
Every time I buy CYGX I have a formula every 1000 shares I have are = to $100,000 dollars in the future that is at a 100 dollar a share price ,I am long and I am very happy to be buying at these levels ,at these levels it is a gift by GOD in my thinking ,If it can only hold at these levels for a few more months that would be good for me ,I know I am being greedy at this point but if we could keep this stock quiet and collect it for a few month more all on this board would be set for life .
Just listened to yesterdays american scene again , the patent covers anti bacterial and anti fungal ,the fungal is new news ,If we can just fight and cure foot and nail fungas this company will be big ,If you remember the lamasil ads on T.V. the list of side effects are long ,including liver and kidney damage , CYTOGENIX with no side effects will rule.
Get us out of berlin ,its not a good place to be right now with all the shorting going on over there , once they clean up the mess then that would be a good time to go back to berlin.
Very good interview on American scene click on below then click the google search then bring arrow half way you will hear Malcolm .
http://archives.warpradio.com/btr/AmericanScene/072810.MP3
Sukycospito this one is in press do you think its the results of the lung study using cygx technology?
Kinsey B, Densmore C, Orson F. (2004). Gene delivery to the lungs by polycations. Polymeric Gene Delivery: Principles and Applications. Edited by M. M. Amiji. (In Press
BAMM market maker is buying at .29 and selling at .51 ,I think we will end up today that would be nice .
Only two hours ago news came out give it a chance lots of people are working and lots of people are trying to get the money to buy .The news about Dr. Charles L. Densmore and baylor college testing of Cytogenix technology may put us on a very big map.
Sukycospito I don't know what is more exciting ,the news today or your find on Dr. Charles L. Densmore ,seems Densmore is the inventor of this aerosol delivery system.If it works this good CYGX should acquire this invention .
I predict a dillinger of news PR's starting RAT-tat-tat-tat.
Sukycospito news says expect to maintain a pace of eight to ten new filings a year ,WOW!
News News world patent
Sukycospito doesn't Cytogenix have a study at Baylor.
Big boards are up today ,It would be nice day for news .I have been buying for the past year and I just bought some today at 10:34 I called up my broker and bought 3000 shares at market .I add when I can little buy little may nest of shares are growing .
hdhick instead of reporting people why not contribute something to this board ,anything that involves cygx would be nice.
It looks good for our company Cytogenix that Malcolm is asked to comment on Shi research ,but remember ,we Cytogenix is involved in the SS dna of silencing cells not Shi research.But again very nice that Malcolm is trusted to comment on such important news.
Malcolm on American scene today 1st hour half way through .
Just got back they did not want me to have any at .29 cents not filled .
I just put a buy order in for 3000 shares for .29 cents I will see if they will let any go .
Thanks tatonkano62 I just found out ,but it makes you think whats new ,if this is a year old news ,what could be in the news next?
yes it is a type o ,it was in 2003
http://www.nature.com/cgi-taf/DynaPage.taf?file=/gt/journal/v10/n20/abs/3302068a.html
Big b ,We are silencing lung cancer cells ,just looked and it is a type o .It was in sept 2003 .
Cytogenix to be in Sept 2004 issue of Gene Therapy read page 8 very interesting ,article 7
http://www.biohouston.org/uploads/BioHouston--Sept%2018,%202003.pdf
Arnold I know your very smart and you got the drift of what I was saying ,that when we get a higher class of people to buy, we will be better off .In the beginning Microsoft had its dips and a stronger base was built ,This is how I feel and I am not making up stuff for positive spins ,and it is good to start with a lead base than a plaster base which we had .Once the drift wood is gone we will go up ,its that simple .I believe that management has a plan to increase PPS before financing to minimize dilution ,and usually these finacing deals are signed on the dotted line that they cannot sell the stock for x amount of years , and the shares cannot be sold in one lump to minimize a down trend .And usually are sold on news or upward trend to let the lender get the biggest bang for their dollar.
Could the recent decline in our stock be good for our company ? I say yes ,It weeds out the weak kneed and puts the stock in the hands of people that know and understand the technology.Malcolm states in the interview on American scene that he wants investors that can understand Cytogenix .He knows that a person of that caliber will hold and strengthen CYGX ,It will be less volitile to day traders, and when the time comes for news and funding ,it will go up with out the sell off because a different class of people will realize the big picture and big potential pay of this stock has .Basically we should end up with a solid lead base of a $1.00 a share in the coming months and will build on that base to new highs.So people don't just tell your friends and family to buy but teach them first about the exciting technology that we have and the absolute enormous potential of Cytogenix. We need smart people that will hold them not fold them.
The bashers are out in full force at Raging Bull ,A good thing? I still think that news is near.
Grrdvm1 you may be right ,news usually comes on Tuesday or friday ,but the way the trading was usually means a news alert.
Arnold once we get off the OTC. BB we will have a more stable stock.